Axial T2-weighted TSE sequence showing signal hyperintensity in the subcortical white matter (U-shaped fibres), which is more pronounced in the frontal lobes (arrows in the upper left image), globi pallidi (arrowhead in the upper right image) and thalami (arrow in the upper right image), brainstem (arrow in the lower left image), and cerebellar white matter, with bilateral, symmetrical involvement.
We present the case of an 8-year-old boy displaying difficulties in gross motor skills and intentional tremor, with onset several months earlier. He had been assessed by the paediatric neurology department at the age of 2 due to initially unilateral ptosis which progressed bilaterally. Neuromuscular disorder was ruled out on several occasions (creatine kinase and anti-acetylcholine receptor antibody determinations, negative results for anti-MuSK antibodies, and negative Tensilon test). The patient's personal history also included thrombocytopaenia secondary to bone marrow hypoplasia, hypoparathyroidism, short stature, and primary adrenal insufficiency. Physical examination revealed bilateral ptosis predominating on the right side, limited facial mimicry, proximal muscle weakness, abolished deep tendon reflexes, and action tremor in both hands, hindering his ability to write. We requested a brain magnetic resonance imaging study, which revealed mild cerebral and cerebellar cortical atrophy with bilateral, symmetrical involvement of subcortical fibres of the supratentorial region; the globi pallidi; the thalami; the cerebellar white matter; and very extensive brainstem atrophy (Fig. 1) . Areas of increased diffusion were observed in the cerebellar lesion, with restriction in the other areas, possibly representing more acute involvement (Fig. 2) . Given the radiological findings supporting the clinical suspicion of Kearns-Sayre syndrome, we requested a blood mitochondrial DNA study, which detected a single 6.4-Kb deletion and a heteroplasmy rate of 27%, confirming the diagnosis. Laboratory testing revealed a low CSF L-5-methyltetrahydrofolate (5-MTHF) level (1.4 nmol/L; normal range: 47-90); we therefore started treatment with oral folinic acid. Although CSF 5-MTHF levels normalised at one year of treatment, the patient presented no clinical or radiological improvement; unlike the cases reported in the literature, we have observed progressive deterioration of his baseline situation, with muscle weakness and cerebellar ataxia increasing in severity. During follow-up, he developed bilateral sensorineural hearing loss; complete atrioventricular block, which required an emergency pacemaker implantation; retinitis pigmentosa; and progressive cerebellar syndrome with gait loss.
